van Driel et al.90 reported results of a randomized trial in which 245 patients with Stage III epithelial ovarian cancer who had received 3 cycles of neoadjuvant chemotherapy underwent interval debulking surgery. These patients were then randomized to receive either 3 more cycles of paclitaxel plus carboplatin with or without hyperthermic intraperitoneal chemotherapy (HIPEC). The addition of HIPEC to interval cytoreductive surgery resulted in longer recurrence-free survival (14.2 months vs 10.7 months) and overall survival (45.7 months vs 33.9 months) and did not result in higher rates of adverse effects. These findings are provocative and raise important questions. Unfortunately, the study did not have an arm with intraperitoneal cisplatin alone without HIPEC,therefore it is not possible to know whether the improved survival was due to the addition of intraperitoneal cisplatin alone or HIPEC. Confirmatory trials are in progress to determine the role of HIPEC.